Africa bears 25% of the global disease burden despite representing less than 20% of the world's population, yet produces less than 6% of its medical supplies, only about one-third of its pharmaceutical needs, and merely 1% of the vaccines it consumes; this structural vulnerability, highlighted during the COVID-19 pandemic, has prompted Kenya to pursue becoming a regional pharmaceutical hub by strengthening its regulatory authority to achieve WHO maturity level three, aiming to address the continent's pharmaceutical expenditure disparity of approximately $25 per capita compared to the global average of over $160.
深度探索
先修知识
- 暂无数据。
后续步骤
- 暂无数据。
深度探索
President William Ruto pushes Kenya’s bid to become a regional pharmaceutical hub本站添加:
news desk and we go to our next where President William Ruto earlier today addressed the Africa initiative for medical access and manufacturing on the sidelines of the Africa forward summit currently being held in Nairobi.
President Ruto highlighted the goal to position Kenya as a regional hub for pharmaceutical manufacturing, health innovation, and medical supply chains serving both the Kenyan and the wider African markets. He added that Kenya is taking deliberate steps to strengthen its pharmaceutical ecosystem by enhancing the capacity of the national regulatory authority to achieve World Health Organization maturity level three, thereby reinforcing global confidence in the quality, safety, and efficacy of Kenyan manufactured products.
Africa bears as has been said here earlier 25% of the global disease burden despite accounting for less than 20% of the world's population.
Yet, our continent still produces less than 6% of its medical supplies, only about 1/3 of its pharmaceutical needs, and a mere 1% of the vaccines it consumes.
And this was starkly reminded to us during the time of COVID.
This is more than a health gap.
It is a structural vulnerability.
Africa's pharmaceutical expenditure stands at approximately $25 per capita compared to a global average of more than $160.
That disparity reflects not only constrained access, but also underdeveloped markets and limited industrial capacity.
Across the continent nearly 700 pharmaceutical manufacturers exist including in Kenya. Yet, most remain small and middle and mid-size, fragmented, and concentrated in only a handful of countries.
This limits scale, limits competitiveness, resilience, and our ability to respond effectively to present and future crisis.
相关推荐
JPMorgan CEO JUST NUKED Mamdani... as NYC's Middle Class COLLAPSES
Englishman-In-NewYork
7K views•2026-05-30
Why Canadians can no longer afford to survive #canada #inflation #shorts
TrueNorthInvestor-v4j
131 views•2026-06-01
The Hidden Difference Between Breakouts & Real Moves #trading #orderflow
SmartMoneyFutures
272 views•2026-06-02
China Is Quietly Buying Gold, the Iran Deal Is Frozen, and Silver Is Heating Up
RichardHolloway0
694 views•2026-05-31
India's Industrialization & China's Reforms
HR-News-Channel
152 views•2026-06-01
Gachagua issues TOUGH DEMANDS to Ruto gvt before reading Ksh.4.8T 2026/7 Budget & Finance Bill 2026
_kenyanewsline
300 views•2026-06-05
Poilievre Blamed Carney for Canada's Recession But the Data Disagrees
Snap-Psychology
596 views•2026-06-01
Uranium Isn’t Priced Like Other Metals
vricmedia
929 views•2026-06-02











